---
title: "Ivonescimab in EGFR-mutated non-small-cell lung cancer: Product information and disease description"
description: "Formulary evidence on Ivonescimab in EGFR-mutated non-small-cell lung cancer: Product information and disease description. Covers Product description and Place of product in therapy. 58 evidence topics quoted from 49 sources."
canonical: "https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/product-information-and-disease-description"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:23-05:00"
---

# Ivonescimab in EGFR-mutated non-small-cell lung cancer: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Investigational status in the United States and approval in China only

> “Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA).”

Source: [Summit Therapeutics ivonescimab overview page](https://smmttx.com/ivonescimab-smt112/ivonescimab-overview/default.aspx)

<a id="topic-2.1.1-2"></a>

##### Regulatory status: Not approved; BLA submitted in the fourth quarter of 2025 and complete response letter issued November 2026

> “today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for ivonescimab in combination with platinum-containing chemotherapy”
> “The CRL indicates that the BLA cannot be approved in its present form, as the FDA determined that substantial evidence of effectiveness is not established in the absence of a statistically significant overall survival (OS) improvement.”

Source: [Summit Therapeutics complete response letter announcement (2026)](https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Provides-Update-Regarding-Ivonescimab-Biologics-License-Application/default.aspx)

> “The BLA was submitted during the fourth quarter of 2025.”

Source: [Summit Therapeutics BLA submission announcement (2026)](https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Announces-Submission-of-Biologics-License-Application-BLA-to-U-S--FDA-Seeking-Approval-for-Ivonescimab-in-Combination-with-Chemotherapy-in-2L-Treatment-of-Patients-with-EGFRm-NSCLC/default.aspx)

> “Based on the results of the HARMONi clinical trial, Summit submitted a BLA in the fourth quarter of 2025 in order to seek approval for ivonescimab plus chemotherapy in this setting.”

Source: [Summit Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000068/smmt-20260630.htm)

<a id="topic-2.1.1-3"></a>

##### Launch

No evidence found.

<a id="topic-2.1.1-4"></a>

##### FDA review milestone

> “PDUFA Goal Action Date of November 14, 2026”

Source: [Summit Therapeutics BLA acceptance announcement (2026)](https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Announces-U-S--FDA-Acceptance-of-Biologics-License-Application-BLA-Seeking-Approval-for-Ivonescimab-in-Combination-with-Chemotherapy-in-Treatment-of-Patients-with-EGFRm-NSCLC-Post-TKI-Therapy/default.aspx)

<a id="topic-2.1.1-5"></a>

##### Special FDA designation

> “The U.S. Food and Drug Administration ("FDA") has granted Fast Track designation for the proposed use of ivonescimab”

Source: [Summit Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1599298/000159929825000048/smmt-20241231.htm)

<a id="topic-2.1.1-6"></a>

##### Authorization outside the United States

> “Ivonescimab was approved for marketing authorization in China in May 2024.”

Source: [Summit Therapeutics China NMPA approval announcement (2024)](https://www.prnewswire.com/news-releases/ivonescimab-in-combination-with-chemotherapy-approved-in-china-by-nmpa-for-2l-egfrm-nsclc-based-on-harmoni-a-clinical-trial-positive-trend-observed-in-overall-survival-towards-ivonescimab-plus-chemotherapy-302161109.html)

Additional sources: [Dhillon (2024)](https://pubmed.ncbi.nlm.nih.gov/39073550/)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Summit Therapeutics

> “Through the License Agreement, the Company obtained the rights to develop and commercialize ivonescimab in the United States, Canada, Europe, and Japan.”
> “Pursuant to the terms of the License Agreement, Summit has final decision-making authority with respect to all of its commercialization activities including, but not limited to, commercial strategy, pricing and reimbursement in the Licensed Territory.”

Source: [Summit Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000068/smmt-20260630.htm)

<a id="topic-2.1.2.1-2"></a>

###### Companies and product names

| Field | Quoted record |
| --- | --- |
| Companies | “Summit Therapeutics Inc. has a definitive partnership with Akeso, Inc.” |
| Product names | “Ivonescimab is known as SMT112 in Summit’s license territories” “and as AK112” |

Source: [Summit Therapeutics Akeso partnership page](https://smmttx.com/ivonescimab-smt112/akeso-partnership/default.aspx)

<a id="topic-2.1.2.1-3"></a>

###### Product and Chinese trade name

> “the Ivonescimab Injection (trade name: 依达方) of Akeso Inc.”

Source: [National Medical Products Administration (2025)](https://english.nmpa.gov.cn/2025-02/19/c_1073557.htm)

<a id="topic-2.1.2.1-4"></a>

###### Drug class

> “a humanized bispecific antibody of IgG1 subtype”

Source: [National Medical Products Administration (2025)](https://english.nmpa.gov.cn/2025-02/19/c_1073557.htm)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Chinese marketed presentation

> “100 mg（10mL）/bottle”

Source: [Akeso ivonescimab product page](https://akesobio.com/en/rd-and-science/products-center/ivonescimab/)

<a id="topic-2.1.2.2-2"></a>

###### Material safety data sheet

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

No evidence found.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### Other classification: bispecific antibody

> “a humanized bispecific antibody of IgG1 subtype”

Source: [National Medical Products Administration (2025)](https://english.nmpa.gov.cn/2025-02/19/c_1073557.htm)

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### HARMONi target population

> “Patients with EGFR+ Non-squamous NSCLC Who Have Progressed After 3rd-Generation EGFR-TKI (osimertinib)”

Source: [Summit Therapeutics HARMONi trial page](https://smmttx.com/clinical-trials/harmoni-clinical-trial/default.aspx)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Mechanism of action

> “Upon administration, ivonescimab simultaneously targets and binds to both PD-1 expressed on certain T cells and VEGF expressed on tumor cells.”

Source: [National Cancer Institute](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ivonescimab)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Preclinical pharmacology

> “ivonescimab forms soluble complexes with VEGF dimers, leading to the enhanced binding avidity of ivonescimab to PD-1”

Source: [Zhong et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11872405/)

<a id="topic-2.1.2.6.2-2"></a>

###### Target engagement in the Chinese phase I study

> “Ivonescimab occupancy on PD-1 sustained over 80% across the treatment period.”
> “Serum VEGF level was rapidly down-regulated after each administration.”

Source: [Wang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11925807/)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Pharmacokinetics: phase I study

> “The half‐life of ivonescimab ranged from 5.0 to 7.3 days following single‐dose administration across all dose levels.”
> “steady state was achieved after 5 doses.”

Source: [Wang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11925807/)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

###### Summary

The Chinese prescribing information warns that immune-related adverse reactions may be severe, life-threatening, or fatal. The trial safety table below reports treatment-related adverse events; it is not U.S. prescribing information.

Source: [Akeso ivonescimab package insert](https://akesobio.com/media/2634/%E4%BE%9D%E6%B2%83%E8%A5%BF%E5%8D%95%E6%8A%97%E6%B3%A8%E5%B0%84%E6%B6%B2-ak112-306-%E8%AF%B4%E6%98%8E%E4%B9%A6-cxss500077-20260811.pdf); [Summit Therapeutics HARMONi longer-term follow-up announcement (2025)](https://smmttx.com/news/press-releases/news-details/2025/Longer-Term-Follow-Up-of-Western-Patients-Showed-Improving-Favorable-Trend-in-Overall-Survival-in-Global-Phase-III-HARMONi-Clinical-Trial-for-Ivonescimab-Plus-Chemotherapy-in-2L-EGFRm-NSCLC/default.aspx)

<a id="topic-2.1.2.7.1-2"></a>

###### Chinese prescribing information: severity of immune-related adverse reactions

> “可能为严重的或危及生命或致死性的”

Source: [Akeso ivonescimab package insert](https://akesobio.com/media/2634/%E4%BE%9D%E6%B2%83%E8%A5%BF%E5%8D%95%E6%8A%97%E6%B3%A8%E5%B0%84%E6%B6%B2-ak112-306-%E8%AF%B4%E6%98%8E%E4%B9%A6-cxss500077-20260811.pdf)

<a id="topic-2.1.2.7.1-3"></a>

###### HARMONi: treatment-related adverse events

| Adverse event category | “Ivonescimab + Chemo(n=219)” | “Placebo + Chemo(n=219)” |
| --- | ---: | ---: |
| “TRAEs Grade 3+” | “50.0%” | “42.2%” |
| “TRAEs Leading to Drug Discontinuation” | “7.3%” | “5.0%” |
| “TRAEs Leading to Death” | “1.8%” | “2.3%” |

Source: [Summit Therapeutics HARMONi longer-term follow-up announcement (2025)](https://smmttx.com/news/press-releases/news-details/2025/Longer-Term-Follow-Up-of-Western-Patients-Showed-Improving-Favorable-Trend-in-Overall-Survival-in-Global-Phase-III-HARMONi-Clinical-Trial-for-Ivonescimab-Plus-Chemotherapy-in-2L-EGFRm-NSCLC/default.aspx)

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Summary

The Chinese prescribing information states that older adults do not require a dose adjustment.

Source: [Akeso ivonescimab package insert](https://akesobio.com/media/2634/%E4%BE%9D%E6%B2%83%E8%A5%BF%E5%8D%95%E6%8A%97%E6%B3%A8%E5%B0%84%E6%B6%B2-ak112-306-%E8%AF%B4%E6%98%8E%E4%B9%A6-cxss500077-20260811.pdf)

<a id="topic-2.1.2.8-2"></a>

###### Chinese prescribing information: dosing in older adults

> “老年患者无需进行剂量调整。”

Source: [Akeso ivonescimab package insert](https://akesobio.com/media/2634/%E4%BE%9D%E6%B2%83%E8%A5%BF%E5%8D%95%E6%8A%97%E6%B3%A8%E5%B0%84%E6%B6%B2-ak112-306-%E8%AF%B4%E6%98%8E%E4%B9%A6-cxss500077-20260811.pdf)

Additional sources: [Zhu et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13220079/)

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Ivonescimab

No evidence found.

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Ivonescimab on Other Drugs

No evidence found.

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### HARMONi dosing

| Treatment phase | Quoted regimen |
| --- | --- |
| Initial treatment | “Ivonescimab 20 mg/kg Q3W” “+Pemetrexed 500 mg/m² Q3W” “+Carboplatin AUC 5 Q3W” “4 cycles (3 weeks/cycle)” |
| Maintenance | “Ivonescimab 20 mg/kg Q3W” “+Pemetrexed 500 mg/m² Q3W” |

Source: [Summit Therapeutics HARMONi enrollment fact sheet (2025)](https://s206.q4cdn.com/652410165/files/doc_downloads/fact-sheets/MAT-SMT112-0070_-HARMONi-Patient-Enrollment-2-pager-Public-April2025-2.pdf)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### HARMONi: administration route and schedule

> “intravenously every 3 weeks.”

Source: [Le et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42636833/)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Expanded access

> “in exceptional circumstances, Summit will consider a treating physician's request for single-patient expanded access to ivonescimab in the United States and Canada”

Source: [Summit Therapeutics expanded access page](https://smmttx.com/clinical-trials/Expanded-Access/default.aspx)

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Chemotherapy partners in the Chinese indication

> “in combination with pemetrexed and carboplatin”

Source: [Akeso ivonescimab product page](https://akesobio.com/en/rd-and-science/products-center/ivonescimab/)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Ivonescimab on Quality Measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Systematic review: included studies and overall survival data

> “5 studies comprising 1,365 patients were included.”
> “as OS data were largely immature or unreported in the included studies”

Source: [Dai et al. (2026)](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1770637/full)

<a id="topic-2.1.2.14-2"></a>

###### Treatment prioritization of chemotherapy-anchored regimens after EGFR-TKI failure

> “Eleven RCTs (n=3,606) were analyzed.”

Source: [Jing et al. (2026)](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1864144/full)

Additional sources: [Zhou et al. (2026)](https://www.dovepress.com/ivonescimab-plus-chemotherapy-versus-bevacizumab-plus-chemotherapy-in--peer-reviewed-fulltext-article-DDDT); [Yang et al. (2026)](https://www.asco.org/abstracts-presentations/265972); [Al Matairi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11818946/); [Pang et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40081325/); [Zhang et al. (2025)](https://journals.sagepub.com/doi/10.1177/17588359251338046); [Chen et al. (2025)](https://journals.sagepub.com/doi/10.1177/17588359251405044)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Somatic EGFR mutations

> “Nearly all these EGFR gene mutations occur during a person's lifetime (somatic) and are present only in cancer cells.”

Source: [MedlinePlus Genetics](https://medlineplus.gov/genetics/gene/egfr/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of EGFR-mutated non-small-cell lung cancer

<a id="topic-2.2.1.2.1-1"></a>

###### Population incidence specific to EGFR-mutated NSCLC

No evidence found.

<a id="topic-2.2.1.2.1-2"></a>

###### Broader context: all lung cancers in the United States

> “228,058 new lung cancers were reported in the United States in 2023”

Source: [CDC (2026)](https://www.cdc.gov/united-states-cancer-statistics/publications/lung-cancer-stat-bite.html)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of EGFR-mutated non-small-cell lung cancer

<a id="topic-2.2.1.2.2-1"></a>

###### Proportion of NSCLC cases with an EGFR mutation

> “An estimated 10–15% of non-small cell lung cancer (NSCLC) cases present with epidermal growth factor receptor mutation (EGFRm).”

Source: [Vanderpoel et al. (2023)](https://link.springer.com/article/10.1007/s41669-023-00407-0)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Broader NSCLC prognosis: stage IV disease

> “Stage IV cancer is almost never cured.”

Source: [MedlinePlus non-small cell lung cancer](https://www.medlineplus.gov/ency/article/007194.htm)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### EGFR pathophysiology

> “These gene changes result in a receptor protein that is constantly turned on (constitutively activated), even when it is not bound to a ligand.”

Source: [MedlinePlus Genetics](https://medlineplus.gov/genetics/gene/egfr/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Genetic testing

> “The best sample for lung cancer genetic tests is tissue from a tumor in your lung.”

Source: [MedlinePlus lung cancer genetic tests](https://medlineplus.gov/lab-tests/lung-cancer-genetic-tests/)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Respiratory and thoracic symptoms

> “Chest pain”
> “Cough that does not go away”
> “Coughing up blood”
> “Shortness of breath”
> “Wheezing”

Source: [MedlinePlus non-small cell lung cancer](https://www.medlineplus.gov/ency/article/007194.htm)

<a id="topic-2.2.1.6-2"></a>

###### Constitutional symptoms

> “Fatigue”
> “Loss of appetite”
> “Losing weight without trying”

Source: [MedlinePlus non-small cell lung cancer](https://www.medlineplus.gov/ency/article/007194.htm)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Case-based evidence: recurrent pleural effusion and atelectasis

> “CT showed recurrent large left pleural effusion with atelectasis, indicating progression.”

Source: [Mo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12753922/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of EGFR-mutated non-small-cell lung cancer

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

Additional sources: [Patel et al. (2026)](https://www.clinical-lung-cancer.com/article/S1525-7304%2826%2900028-8/fulltext)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### U.S. healthcare resource use and costs

> “409 patients with EGFRm advanced NSCLC”
> “Mean all-cause costs PPPM were $27 751 in 1L, $28 971 in 2L, and $31 251 in 3L.”

Source: [Waterhouse et al. (2025)](https://jheor.org/article/142771-healthcare-resource-use-healthcare-costs-and-unmet-needs-among-patients-treated-for-egfr-mutated-advanced-or-metastatic-non-small-cell-lung-cancer)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of EGFR-mutated non-small-cell lung cancer on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Broader NSCLC evidence: reduced caregiver working hours

> “NSCLC and BC caregivers worked 61% and 68%, respectively, of the hours relative to prediagnosis”

Source: [Chiu et al. (2022)](https://journals.sagepub.com/doi/10.1177/23814683221113846)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Biomarker-testing cost components

> “Testing costs (including retesting) encompassed personnel costs, consumables, equipment, and overheads.”

Source: [Malapelle et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11886603/)

<a id="topic-2.2.1.8.4-2"></a>

###### NGS versus single-gene testing: current-practice scenario, 2023–2024

> “26% lower for NGS than for SGT in the CP scenario.”

Source: [Malapelle et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11886603/)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 EGFR Tyrosine Kinase Inhibitors

<a id="topic-2.2.2.1.1-1"></a>

###### First-line therapy for classical activating EGFR mutations

> “third-generation EGFR TKIs, such as osimertinib, should be the preferred first-line option”

Source: [Lee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11648200/)

Additional sources: [Vyas et al. (2026)](https://link.springer.com/article/10.1007/s11912-026-01751-0)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Platinum-based Chemotherapy

<a id="topic-2.2.2.1.2-1"></a>

###### First-line targeted therapy plus chemotherapy

> “osimertinib combined with carboplatin-pemetrexed”

Source: [Lee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11648200/)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 EGFR/MET Bispecific Antibodies

<a id="topic-2.2.2.1.3-1"></a>

###### First-line combination option

> “lazertinib combined with amivantamab”

Source: [Lee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11648200/)

<a id="topic-2.2.2.1.3-2"></a>

###### Treatment alternatives: amivantamab with chemotherapy

> “amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) with carboplatin and pemetrexed”
> “whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.”

Source: [FDA (2024)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-amivantamab-vmjw-carboplatin-and-pemetrexed-non-small-cell-lung-cancer-egfr-exon-19)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Antibody-drug Conjugates

<a id="topic-2.2.2.1.4-1"></a>

###### Treatment alternatives: datopotamab deruxtecan

> “granted accelerated approval to datopotamab deruxtecan-dlnk”
> “who have received prior EGFR-directed therapy and platinum-based chemotherapy.”

Source: [FDA (2025)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Antiangiogenic Combination Therapy

<a id="topic-2.2.2.1.5-1"></a>

###### EGFR-TKI and antiangiogenic combinations

> “erlotinib-bevacizumab”
> “erlotinib-ramucirumab”

Source: [Lee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11648200/)

<a id="topic-2.2.2.1.5-2"></a>

###### CSCO guideline: post-resistance EGFR-mutant NSCLC

> “Ivonescimab plus chemotherapy maintains a Class I recommendation.”

Source: [Akeso (2026)](https://www.prnewswire.com/news-releases/ivonescimab-receives-major-recommendations-across-multiple-therapies-in-the-2026-csco-nsclc-guideline-302755438.html)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Surgical Resection

<a id="topic-2.2.2.1.6-1"></a>

###### Broader NSCLC standard of care: stage I disease

> “Surgery is the treatment of choice for patients with stage I NSCLC.”

Source: [PDQ Adult Treatment Editorial Board (2025)](https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Radiotherapy

<a id="topic-2.2.2.1.7-1"></a>

###### Broader NSCLC care: palliation of local symptoms

> “Radiation therapy may be effective in palliating symptomatic local involvement with NSCLC”

Source: [PDQ Adult Treatment Editorial Board (2025)](https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 Supportive and Palliative Care

<a id="topic-2.2.2.1.8-1"></a>

###### Integration throughout cancer treatment

> “Palliative care may be provided at any point during cancer care”

Source: [National Cancer Institute (2021)](https://www.cancer.gov/about-cancer/advanced-cancer/care-choices/palliative-care-fact-sheet)

Additional sources: [Lee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11648200/)

<a id="heading-2.2.2.1.9"></a>

###### 2.2.2.1.9 Limitations of Current Therapies

<a id="topic-2.2.2.1.9-1"></a>

###### Summary

Post-EGFR-TKI treatment options include amivantamab plus carboplatin and pemetrexed and, after prior EGFR-directed therapy and platinum chemotherapy, datopotamab deruxtecan. These options occupy different treatment positions. HARMONi compared ivonescimab plus chemotherapy with placebo plus chemotherapy, not with either of these active combination or antibody-drug conjugate strategies. Its results therefore do not establish superiority over those alternatives.

Source: [FDA (2024)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-amivantamab-vmjw-carboplatin-and-pemetrexed-non-small-cell-lung-cancer-egfr-exon-19); [FDA (2025)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer); [Le et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42636833/)

<a id="topic-2.2.2.1.9-2"></a>

###### Unmet need

> “Patients with advanced EGFR-variant NSCLC whose disease progresses after EGFR-TKI therapy have few effective treatment options.”

Source: [JAMA Research Summary (2026)](https://jamanetwork.com/journals/jama/fullarticle/2850532)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

The U.S. development setting is ivonescimab plus chemotherapy after progression on a third-generation EGFR TKI in EGFR-mutated nonsquamous NSCLC. Treatment in HARMONi was intravenous every 3 weeks. Summit reported a November 14, 2026 FDA action date, announced on November 15, 2026 that the FDA had issued a complete response letter, and estimates that more than 14,000 U.S. patients could be eligible annually. That estimate describes a potential treatment population, not the incidence of EGFR-mutated NSCLC.

Ivonescimab has been authorized in China since May 2024. Akeso reports a Class I CSCO recommendation for ivonescimab plus chemotherapy after EGFR-TKI resistance. In the United States and Canada, Summit describes exceptional single-patient expanded access rather than routine commercial access.

Source: [Summit Therapeutics HARMONi trial page](https://smmttx.com/clinical-trials/harmoni-clinical-trial/default.aspx); [Le et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42636833/); [Summit Therapeutics BLA acceptance announcement (2026)](https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Announces-U-S--FDA-Acceptance-of-Biologics-License-Application-BLA-Seeking-Approval-for-Ivonescimab-in-Combination-with-Chemotherapy-in-Treatment-of-Patients-with-EGFRm-NSCLC-Post-TKI-Therapy/default.aspx); [Summit Therapeutics China NMPA approval announcement (2024)](https://www.prnewswire.com/news-releases/ivonescimab-in-combination-with-chemotherapy-approved-in-china-by-nmpa-for-2l-egfrm-nsclc-based-on-harmoni-a-clinical-trial-positive-trend-observed-in-overall-survival-towards-ivonescimab-plus-chemotherapy-302161109.html); [Akeso (2026)](https://www.prnewswire.com/news-releases/ivonescimab-receives-major-recommendations-across-multiple-therapies-in-the-2026-csco-nsclc-guideline-302755438.html); [Summit Therapeutics expanded access page](https://smmttx.com/clinical-trials/Expanded-Access/default.aspx); [Summit Therapeutics complete response letter announcement (2026)](https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Provides-Update-Regarding-Ivonescimab-Biologics-License-Application/default.aspx)

<a id="topic-2.2.2.2-2"></a>

###### Anticipated U.S. population

> “Over 14,000 U.S. Patients Eligible for Treatment Each Year”

Source: [Summit Therapeutics BLA acceptance announcement (2026)](https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Announces-U-S--FDA-Acceptance-of-Biologics-License-Application-BLA-Seeking-Approval-for-Ivonescimab-in-Combination-with-Chemotherapy-in-Treatment-of-Patients-with-EGFRm-NSCLC-Post-TKI-Therapy/default.aspx)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Summary

The geographically stratified survival update and individual case reports describe possible variation in treatment outcomes. The case reports do not establish comparative treatment effects or validate predictive biomarkers. The reported geographic HRs should not be interpreted as proof that treatment effects are identical across regions.

Source: [Summit Therapeutics HARMONi updated overall survival announcement (2026)](https://smmttx.com/news/press-releases/news-details/2026/Ivonescimab-Plus-Chemotherapy-Shows-Consistent-Favorable-Overall-Survival-Results-in-Western-and-Asian-Patients-in-Updated-Analysis-from-Global-Phase-III-HARMONi-Study/default.aspx); [Mo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12753922/); [Pan et al. (2025)](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1707096/full)

<a id="topic-2.2.2.3-2"></a>

###### HARMONi: updated survival by geographic population

> “A hazard ratio of 0.76 was observed in both the full intention-to-treat population and the subgroup of western patients.”

Source: [Summit Therapeutics HARMONi updated overall survival announcement (2026)](https://smmttx.com/news/press-releases/news-details/2026/Ivonescimab-Plus-Chemotherapy-Shows-Consistent-Favorable-Overall-Survival-Results-in-Western-and-Asian-Patients-in-Updated-Analysis-from-Global-Phase-III-HARMONi-Study/default.aspx)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Multidisciplinary palliative and oncology care coordination

> “The palliative care team works together with the oncology care team”

Source: [National Cancer Institute (2021)](https://www.cancer.gov/about-cancer/advanced-cancer/care-choices/palliative-care-fact-sheet)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

No evidence found.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

No evidence found.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Broader stage IV NSCLC treatment goals

> “The goals of therapy are to extend and improve the quality of life.”

Source: [MedlinePlus non-small cell lung cancer](https://www.medlineplus.gov/ency/article/007194.htm)

## Related pages
- [Ivonescimab: EGFR-mutated non-small-cell lung cancer](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer.md)
- [Ivonescimab in EGFR-mutated non-small-cell lung cancer: Terms and abbreviations](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/terms-and-abbreviations.md)
- [Ivonescimab: EGFR-mutated non-small-cell lung cancer](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/executive-summary.md)
- [Ivonescimab in EGFR-mutated non-small-cell lung cancer: Clinical evidence](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/clinical-evidence.md)
- [Ivonescimab in EGFR-mutated non-small-cell lung cancer: Economic information and modeling report](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/economics.md)
- [Ivonescimab in EGFR-mutated non-small-cell lung cancer: References](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/references) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/references.md)
- [Ivonescimab in EGFR-mutated non-small-cell lung cancer: prevalence by geography](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/prevalence) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/prevalence.md)
- [Ivonescimab in EGFR-mutated non-small-cell lung cancer: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/cost-effectiveness-analyses.md)
